UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211041961-17588359211041961

2021

Volltextzugriff (PDF)

A role for fulvestrant monotherapy in the first‐line treatment of ER+ metastatic breast cancer?

The breast journal, 2020-02, Vol.26 (2), p.109-111

Mahtani, Reshma L.

2020

Volltextzugriff (PDF)

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review

Clinical therapeutics, 2009, Vol.31, p.2371-2378

2009

Volltextzugriff (PDF)

Insomnia in the Cancer Patient: A Complex Problem

The breast journal, 2017-07, Vol.23 (4), p.385-386

Mahtani, Reshma L.

2017

Volltextzugriff (PDF)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer

The oncologist (Dayton, Ohio), 2023-05, Vol.28 (5), p.414-424

2023

Volltextzugriff (PDF)

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

Supportive care in cancer, 2022-07, Vol.30 (7), p.6135-6144

2022

Volltextzugriff (PDF)

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Breast Cancer: Basic and Clinical Research, 2015-01, Vol.2015 (2015), p.9-17

2015

Volltextzugriff (PDF)

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2―Positive, Locally Advanced, or Metastatic Breast Cancer

Journal of clinical oncology, 2014-05, Vol.32 (14), p.1437-1444

2014

Volltextzugriff (PDF)

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Supportive care in cancer, 2022-10, Vol.30 (10), p.7913-7922

2022

Volltextzugriff (PDF)

When Can a Salvage Therapy (T-DM1) Take the Lead?

Journal of clinical oncology, 2016-10, Vol.34 (29), p.3492-3494

2016

Volltextzugriff (PDF)

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.617-624

2015

Volltextzugriff (PDF)

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Cancer management and research, 2019-01, Vol.11, p.513-524

2019

Volltextzugriff (PDF)

Comparative effectiveness of early-line nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

Cancer management and research, 2018-01, Vol.10, p.249-256

2018

Volltextzugriff (PDF)

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.7-14

2014

Volltextzugriff (PDF)

Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract

The oncologist (Dayton, Ohio), 2008-01, Vol.13 (1), p.39-50

2008

Volltextzugriff (PDF)

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5823-5824

2008

Volltextzugriff (PDF)

Racial and ethnic disparities in hospital outcomes following hospitalizations for mastectomy for breast cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13691-e13691

2024

Volltextzugriff (PDF)

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13068-e13068

2023

Volltextzugriff (PDF)

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN)

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.314-314

2021

Volltextzugriff (PDF)

Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer

Oncology (Williston Park, N.Y.), 2021-06, Vol.35 (6), p.350

2021

Volltextzugriff (PDF)

Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1036-1036

2024

Volltextzugriff (PDF)

Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13097-e13097

2024

Volltextzugriff (PDF)

Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.10598-10598

2021

Volltextzugriff (PDF)

Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18836-e18836

2023

Volltextzugriff (PDF)

Characterization of first-line use of cyclin dependent kinase 4/6 (CDK4/6) inhibitors in metastatic breast cancer among Florida health care systems

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19347-e19347

2020

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US

A role for fulvestrant monotherapy in the first‐line treatment of ER+ metastatic breast cancer?

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review

Insomnia in the Cancer Patient: A Complex Problem

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2―Positive, Locally Advanced, or Metastatic Breast Cancer

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

When Can a Salvage Therapy (T-DM1) Take the Lead?

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Comparative effectiveness of early-line nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

Racial and ethnic disparities in hospital outcomes following hospitalizations for mastectomy for breast cancer

Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN)

Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer

Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy

Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study

Outcomes among Hispanic metastatic breast cancer patients treated with alpelisib and fulvestrant: Single institution retrospective study

Characterization of first-line use of cyclin dependent kinase 4/6 (CDK4/6) inhibitors in metastatic breast cancer among Florida health care systems

Suchergebnisse filtern